WO1997020559A1 - Verwendung fungizider mittel zur selektiven dekontamination von zähnen und zahnersatz - Google Patents
Verwendung fungizider mittel zur selektiven dekontamination von zähnen und zahnersatz Download PDFInfo
- Publication number
- WO1997020559A1 WO1997020559A1 PCT/EP1996/005131 EP9605131W WO9720559A1 WO 1997020559 A1 WO1997020559 A1 WO 1997020559A1 EP 9605131 W EP9605131 W EP 9605131W WO 9720559 A1 WO9720559 A1 WO 9720559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- atoms
- dentures
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- fungal prostheses are a significant risk factor for predisposed patients, even if there are no clinical signs of a disease in the mouth preferred to an infection by fungi, because the infection defense is weakened at these places.
- diabetics, asthmatics, smokers, AIDS sufferers, transplant patients or people who are treated with antibiotics or immunosuppressive drugs represent risk groups for recurrent mycoses
- the documents EP 0 241 91 8 and EP 0 226 984 describe the anti-mycotic properties of some 1-hydroxy-2-pyridone derivatives.
- Other antifungal 1-hydroxy-2-pyridone derivatives are described in US Pat. No. 3,968,111 8 known
- the object of the present invention is to provide fungicidal agents which enable adequate and permanent growth inhibition and / or killing of fungi on teeth and dentures, in particular outside the mouth area.
- a compound of Formet I is excellently suitable for inhibiting the growth and / or killing of fungi on teeth or dentures, because this compound has good adsorption on the smooth surface of the teeth or dentures and therefore not only adequate mortality the fungus causes, but also a renewed colonization of the surface difficult. Furthermore, the compound of the formula I shows a strong inhibitory action against fluconazole-resistant strains of the human pathogenic Candida species.
- the invention therefore relates to the use of the compound of the formula I.
- R 1 , R 2 and R 3 which are identical or different, denote hydrogen atom or alkyl having 1 to 4 carbon atoms, and
- R 4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
- Y hydrogen atom or up to 2 halogen atoms such as chlorine and / or
- Z is a single bond or the divalent radicals O, S, -CR -
- R H or C 1 -C 4 alkyl or other divalent radicals with 2-10 chain-linked C and optionally O and / or S atoms, where - if the radicals 2 or more 0- and / or S - Contain atoms - the latter must be separated from one another by at least 2 C atoms and where 2 adjacent C atoms can also be linked to one another by a double bond and the free valences of the C atoms by H and / or C -, - C 4 - Alkyl groups are saturated means
- Ar is an aromatic ring system with up to two rings, which can be substituted by up to three radicals from the group fluorine, chlorine, bromine, methoxy, C, -C 4 -alkyl, trifluoromethyl and trifluoromethoxy, for decontamination of teeth or dentures .
- the invention further relates to the use of the compound of formula I for the decontamination of dentures outside the mouth.
- the C chain links are preferably CH 2 groups. If the CH 2 groups are substituted by C 1 -C 4 alkyl groups, CH 3 and C 2 H 5 are preferred substituents. Exemplary residues "Z" are
- Ar means phenyl and condensed systems such as naphthyl, tetrahydronaphthyl and indenyl, as well as isolated systems such as those derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.
- dentures is understood to mean means for correcting or replacing the dentition or denture parts, such as dental bridges, braces, dental splints, crowns or implants, as well as artificial dentures or denture parts.
- Denture materials are, for example, plastics, porcelain or metal parts, preferably porcelain.
- the fungi which can be treated according to the invention are all types of fungi which occur in the mouth and throat area, in particular Candida albicans, Candida glabrata, Candida tropicahs, azole-resistant fungi or azole-resistant yeasts
- azole-resistant fungi is understood to mean all types of fungus or yeast which have become resistant to antifungals, for example to antifungals which contain azole residues in the molecule, such as fluconazole.
- Decontamination means the inhibition of growth or killing of fungi or yeast.
- the "mouth area” encloses the lips, teeth, palate, tongue, oral mucous membranes and throat.
- Immunosuppressed denture carriers are preferably treated, such as diabetics, asthmatics, smokers, AIDS sufferers, patients before and after transplants, cancer patients, patients who are treated for a long time with antibiotics, cytostatics or corticosteroids, patients with antifungal fungi, in particular patients with fluconazole -resistant mushrooms or the elderly
- the invention further relates to dentures containing a compound of formula I.
- the compound of formula I can lie on the surface of the denture, be impregnated with it, or the compound of formula I can coat the denture with or without auxiliary substances
- the preparation of the dental prosthesis according to the invention and the use of the compound of the formula I for the decontamination of dental prostheses outside the mouth area are carried out by incubation with the compound of the formula I, for example by spraying, application, immersion or incubation with a solution, gel containing a compound of the formula I, varnish, effervescent tablet or suspension.
- the application on the teeth or dentures in the mouth area is carried out by spraying, gargling or application with a solution, gel, lozenge or suspension containing a compound of the formula I.
- the compound of formula I is expediently used by means of preparations customary in cosmetics and dermatology, for. B. soaps, syndet soaps, washing solutions, washing cream, toothpaste, water / alcoholic solutions, suspensions, gels or film-forming preparations. Aqueous / alcoholic solutions or dispersion concentrates are preferred.
- Such preparations can also contain other additives in addition to the customary auxiliaries known from the literature, for.
- film formers e.g. Example, poly-N-vinylpyrrolidone and alkyl-substituted poly-N-vinylpyrrolidones
- the preparations are prepared in a manner known per se by combining the individual components and, if necessary, further processing adapted to the respective preparation type (EP 0 288 945, EP 0 649 660). Some of these diverse possible preparation forms are described in the exemplary embodiments
- the compound of formula I or its salts are used in amounts between about 0.1% and about 5% against fungi or yeast. Within this range, the concentrations of the special preparations depend on their intended use.
- Preparations that only remain on the denture for a short time after application and are rinsed off again e.g. B. soaps, washing solutions, toothpastes or washing creams, contain the compound of formula I in concentrations of about 1% to about 5%, preferably from 0.5% to 2%. In preparations which are intended to remain on the dentures, such as suspensions or gels, lower concentrations of approximately 0.1% to 1% are appropriate.
- the invention further relates to the use of dentures containing the compound of formula I for the prophylaxis and treatment of fungal infections in the mouth
- the invention further relates to the use of the compound of formula I for the manufacture of a medicament for the treatment of diseases which are caused by azole-resistant fungi or azole-resistant yeasts.
- Example 1 The compound according to Example 1 (1.0 g), Lipoid S 75 (1.8, 75 g), Cremophor RH 40 (6.25 g) and Glycofurol (74.0 g) are mixed and mixed with water to a final concentration of 0 , 1% of the compound diluted according to Example 1.
- Azole-resistant strains of Candida albicans are isolated in patients who, for example, are treated with fluconazole (Diflucan ® ) for more than one year. For this purpose, samples are taken from the patient in the mouth area and undiluted or diluted 1: 1 00 on an RPMI 1 640 agar (Gibco / BRL, Life Technologies GmbH, 76339 Eggenstein, Germany) applied, which contains about 1.0 ⁇ g / ml fluconazole. Resistant Candida albicans strains are isolated, further purified on agar and kept isolated in peptone dextrose agar tubes. The Candida albicans strains 94/3 and 94/57 are isolated.
- the activity of the compound according to Example 1 is determined using the microtiter dilution technique in RPMI 1 640 medium.
- the growth medium RPMI 1 640 buffered with 0.165 M morphohnpropanesulfonic acid pH 7.0, is filled into 96-well microtiter plates.
- the compound according to Example 1 is serially diluted by a factor of 2, so that final concentrations of 256 to 0.002 // g / ml of compound 1 and fluconazole are obtained.
- the microtiter plates prepared in this way are inoculated with the fungi Candida albicans ATCC 90028 and Candida albicans ATCC 90029 (both not resistant to fluconazole) and with the isolates Candida albicans 94/3 and 94/57 (both resistant to fluconazole).
- the initial cell count is 1 - 5 * 1 0 3 colony-forming units per ml of growth medium.
- the microtiter plates are incubated at 35 ° C for 48 hours.
- the minimum inhibitory concentration is determined photometrically at 510 nm. Table 1 shows the results: Table 1
- Table 1 shows that the compound according to Example 1 prevents both fluconazole-resistant and non-resistant C. albicans strains from growing Example 4
- Candida albicans cells are incubated in glass tubes with the compound according to Example 1 (1.0 mg / g) for 10 or 20 minutes. The samples are then sterile filtered and the concentration of the compound according to Example 1 is determined in the cell-free supernatants. Table 2 shows the results:
- the compound according to Example 1 strongly adsorbed on the Candida albicans cells and on the sample vessel walls.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pest Control & Pesticides (AREA)
- Birds (AREA)
- Agronomy & Crop Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96939874A EP0865277A1 (de) | 1995-12-04 | 1996-11-21 | Verwendung fungizider mittel zur selektiven dekontamination von zähnen und zahnersatz |
KR1019980704170A KR19990071885A (ko) | 1995-12-04 | 1996-11-21 | 치아 및 의치의 선택적인 오염 제거를 위한 살균제의 용도 |
AU76950/96A AU7695096A (en) | 1995-12-04 | 1996-11-21 | Use of fungicidal agents for selective decontamination of teeth and dental prostheses |
JP9520919A JP2000505782A (ja) | 1995-12-04 | 1996-11-21 | 歯および義歯の選択的汚染除去のための殺真菌剤の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19545139A DE19545139C1 (de) | 1995-12-04 | 1995-12-04 | Verwendung fungizider Mittel zur selektiven Dekontamination von Zahnersatz |
DE19545139.2 | 1995-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997020559A1 true WO1997020559A1 (de) | 1997-06-12 |
Family
ID=7779119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/005131 WO1997020559A1 (de) | 1995-12-04 | 1996-11-21 | Verwendung fungizider mittel zur selektiven dekontamination von zähnen und zahnersatz |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0865277A1 (de) |
JP (1) | JP2000505782A (de) |
KR (1) | KR19990071885A (de) |
AU (1) | AU7695096A (de) |
CA (1) | CA2239409A1 (de) |
DE (1) | DE19545139C1 (de) |
WO (1) | WO1997020559A1 (de) |
ZA (2) | ZA9610134B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005001990A1 (de) * | 2005-01-15 | 2006-07-20 | Clariant Gmbh | Wässrige fungizide Zubereitungen |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968118A (en) * | 1968-08-31 | 1976-07-06 | Hoechst Aktiengesellschaft | Process for the manufacture of 1-hydroxy-2-pyridones |
EP0241918A2 (de) * | 1986-04-18 | 1987-10-21 | Hoechst Aktiengesellschaft | 1-Hydroxy-2-pyridone, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten, sowie bei der Herstellung der 1-Hydroxy-2-pyridone gebildete Zwischenprodukte |
EP0381446A1 (de) * | 1989-01-31 | 1990-08-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Oral anzuwendende antifungale Arzneizubereitungen |
JPH0782126A (ja) * | 1993-09-10 | 1995-03-28 | Lion Corp | 口腔用組成物 |
-
1995
- 1995-12-04 DE DE19545139A patent/DE19545139C1/de not_active Expired - Fee Related
-
1996
- 1996-11-21 CA CA002239409A patent/CA2239409A1/en not_active Abandoned
- 1996-11-21 WO PCT/EP1996/005131 patent/WO1997020559A1/de not_active Application Discontinuation
- 1996-11-21 JP JP9520919A patent/JP2000505782A/ja active Pending
- 1996-11-21 EP EP96939874A patent/EP0865277A1/de not_active Withdrawn
- 1996-11-21 KR KR1019980704170A patent/KR19990071885A/ko not_active Application Discontinuation
- 1996-11-21 AU AU76950/96A patent/AU7695096A/en not_active Abandoned
- 1996-12-03 ZA ZA9610134A patent/ZA9610134B/xx unknown
- 1996-12-03 ZA ZA9610133A patent/ZA9610133B/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968118A (en) * | 1968-08-31 | 1976-07-06 | Hoechst Aktiengesellschaft | Process for the manufacture of 1-hydroxy-2-pyridones |
EP0241918A2 (de) * | 1986-04-18 | 1987-10-21 | Hoechst Aktiengesellschaft | 1-Hydroxy-2-pyridone, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten, sowie bei der Herstellung der 1-Hydroxy-2-pyridone gebildete Zwischenprodukte |
EP0381446A1 (de) * | 1989-01-31 | 1990-08-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Oral anzuwendende antifungale Arzneizubereitungen |
JPH0782126A (ja) * | 1993-09-10 | 1995-03-28 | Lion Corp | 口腔用組成物 |
Non-Patent Citations (3)
Title |
---|
BRAGA ET AL: "Inhibition of Candida Albicans Adhesiveness to Human Buccal and Vaginal cells by Sub-inhibitory Concentration of Rilopirox", ARZNEIMITTEL-FORSCHUNG, vol. 45, no. 1, 1995, GERMANY, pages 84 - 87, XP002027401 * |
HAENEL ET AL: "Evaluation of Fungicidal Action in vitro and in a Skin Model", ANNALS NEW YORK ACADEMY OF SCIENCES, vol. 544, 1988, NEW YORK, pages 329 - 337, XP000651698 * |
PATENT ABSTRACTS OF JAPAN vol. 95, no. 003 * |
Also Published As
Publication number | Publication date |
---|---|
AU7695096A (en) | 1997-06-27 |
ZA9610133B (en) | 1997-06-04 |
DE19545139C1 (de) | 1997-04-17 |
ZA9610134B (en) | 1997-06-04 |
KR19990071885A (ko) | 1999-09-27 |
JP2000505782A (ja) | 2000-05-16 |
CA2239409A1 (en) | 1997-06-12 |
EP0865277A1 (de) | 1998-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brecx et al. | Efficacy of Listerine®, Meridol® and chlorhexidine mouthrinses on plaque, gingivitis and plaque bacteria vitality | |
DE60212683T2 (de) | Pharmazeutische und kosmetische zusammensetzungen mit oxy-gruppen-tragenden aromatischen aldehyden | |
DE112008001301T5 (de) | Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm | |
DE3726176C2 (de) | Mittel in Form eines Gels zur Förderung und Stimulierung des Haarwachstums und zur Verringerung von Haarausfall auf Basis von Piperidino-Pyrimidin-Derivaten | |
EP0150374B1 (de) | Mund- und Zahnpflegemittel | |
EP0777457B1 (de) | Die verwendung von glyceryltriacetat zur behandlung von onychomykosen | |
EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
DE2711087C2 (de) | ||
DE60026491T2 (de) | Melagatran zur behandlung von entzündungen | |
DE3119746A1 (de) | Verfahren zur herstellung eines antimikrobiellen wirkstoffes, nach dem verfahren hergestellter wirkstoff sowie dessen verwendung | |
EP0480172B1 (de) | Zahnpflegemittel | |
DE19643831A1 (de) | Verwendung von 1-Hydroxy-2-pyridonen zur Behandlung von schwer therapierbaren Schleimhauterkrankungen | |
DE2140719A1 (de) | Arzneimittel auf der Grundlage eines Pyrazolons | |
DE69906701T2 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
DE2349538C2 (de) | Arzneimittel zur Behandlung von Lebererkrankungen | |
DE3640409A1 (de) | Aeusserlich anwendbare komposition | |
DE19545139C1 (de) | Verwendung fungizider Mittel zur selektiven Dekontamination von Zahnersatz | |
DE2557431C2 (de) | Topisch anwendbares antimikrobielles Präparat | |
DE69733037T2 (de) | Schutz zur verminderung von zahnbelag | |
DE2716144C2 (de) | ||
EP0865278B1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen | |
DE3827515A1 (de) | Pharmazeutische praeparate fuer die topische anwendung | |
DE3236191C2 (de) | Chlorhexidin-Dinaproxenat, Verfahren zu dessen Herstellung, sowie dieses enthaltende anti-entzündliche, desinfizierende und anti-bakterielle Zusammensetzung | |
DE2235348A1 (de) | Heilmittel zur behandlung der gonorrhoe sowie dessen verwendung | |
DE2426393C3 (de) | Gebrauchsfertiges flüssiges Gurgelmittel mit antimikrobieller Wirksamkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ EE HU IL JP KR LT LV MX NO NZ PL RO RU SG SI SK TR UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996939874 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2239409 Country of ref document: CA Ref country code: CA Ref document number: 2239409 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1997 520919 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980704170 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1996939874 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980704170 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996939874 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980704170 Country of ref document: KR |